Pfizer says it applied for Japan gov't approval for oral COVID-19 drug | Inquirer News
Close  

Pfizer says it applied for Japan gov’t approval for oral COVID-19 drug

/ 12:40 PM January 14, 2022
FILE PHOTO: A 3D printed Pfizer logo is placed near medicines from the same manufacturer in this illustration taken September 29, 2021. REUTERS/Dado Ruvic/Illustration

FILE PHOTO: A 3D printed Pfizer logo is placed near medicines from the same manufacturer in this illustration taken September 29, 2021. REUTERS/Dado Ruvic/Illustration

TOKYO —  U.S. drugmaker Pfizer Inc said on Friday it has applied for Japanese government approval for its oral COVID-19 treatment.

The application is based on global Phase II/III trials that Japan was part of, Pfizer said in a statement.

ADVERTISEMENT

With COVID-19 cases surging again, Japan is betting heavily on oral treatments to keep serious infections and deaths at bay. Prime Minister Fumio Kishida said last week he aimed to distribute the Pfizer pills next month after securing 2 million doses during a December call with Chief Executive Albert Bourla.

The government has already started distributing molnupiravir antiviral pills after agreeing to pay Merck & Co Inc and its partner Ridgeback Biotherapeutics about $1.2 billion for 1.6 million courses.

FEATURED STORIES

Japan’s Shionogi & Co Ltd is working on its own pill, with plans to supply 1 million doses this year.

The highly infectious Omicron variant is driving a surge in COVID-19 cases. Japan recorded 18,859 new infections on Thursday, according to a tally by national broadcaster NHK, the most since Sept. 2 during what was the country’s fifth wave of the pandemic.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.
Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: Japan, Omicron variant, oral COVID-19 drug, Paxlovid, Pfizer
For feedback, complaints, or inquiries, contact us.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and
acknowledge that I have read the Privacy Policy.



© Copyright 1997-2022 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.